Wayback Machine
Nov DEC Jan
Previous capture 21 Next capture
2014 2015 2016
1 captures
21 Dec 15 - 21 Dec 15
sparklines
Close Help
Denosumab May Warrant Further Testing in Patients Receiving Long-Term GC Therapy

Summary

Although glucocorticoids (GCs) are a backbone of the treatment of rheumatic diseases, they are the major cause of secondary osteoporosis and are associated with increased fracture rate and decreased bone quality. This article discusses outcomes from Denosumab in Current Users of Bisphosphonates for Glucocorticoid-Induced Osteoporosis [NCT01465568].

  • Metabolic Bone Disease
  • Rheumatoid Arthritis
  • Lupus Clinical Trials
  • Metabolic Bone Disease
  • Rheumatoid Arthritis
  • Rheumatology
  • Lupus
  • Rheumatology Clinical Trials
View Full Text